Research and Clinical Trials

Brief Description  
This study is to describe neurocognitive function in patients with relapsing multiple sclerosis (RMS) treated with LEMTRADA® in routine clinical practice as measured by the Multiple Sclerosis Cognitive (MS-COG) composite score. Additional neurocognitive tests will also be administered and reviewed as well as MRI data when available. The study includes a screening period of up to 30 days followed by a baseline visit, month 12 and month 24/EQS visit for a total of four visits.
Who may be Eligible  
Patients with relapsing forms of MS aged 25-55 years old who are selected for treatment for treatment with Lemtrada(® and enrolled in the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program in the US are eligible for this study. The decision to treat with LEMTRADA(® will be done prior to and independent of the proposal to enroll in this study. To participate, patients must be able to give signed written informed consent.
Start Date  
IRB Number  
Principal Investigator  
Graves, Donna
Contact Name  

For More Information, Contact   Nicol  M.  Brandon
Phone:  (704) 446-1910  Fax:  (704) 446-6208 

Address:  1010 Edgehill Road, North
Charlotte, NC 28207